Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference

About this update from Niagen Bioscience, Inc.

LOS ANGELES --(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp. ), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried , and Chief Financial Officer, Ozan Pamir , will participate in Canaccord Genuity’s 45th Annual Growth Conference, taking place from August 12 to 14, 2024 , in Boston . Mr. Fried is scheduled to participate in a fireside chat on Tuesday, August 12 , at 12:00 p.m. Eastern Time ( 9:00 a.m. Pacific Time ). To register for the Niagen Bioscience fireside chat webcast, please visit www.wsw.com . Mr. Fried and Mr. Pamir will also hold one-on-one meetings with institutional investors throughout the conference. To arrange a meeting, please visit the conference website here or contact your CG representative. A replay of the fireside chat webcast will be available on the Niagen Bioscience Investor Relations website, www.investors.niagenbioscience.com , following the event. For additional information on Niagen Bioscience , visit www.niagenbioscience.com . About Niagen Bioscience : Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp. , is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States † (available at www.truniagen.com ), and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( www.niagenplus.com ). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com , where copies of press releases, news, and financial information are regularly published. †Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). View source version on businesswire.com : https://www.businesswire.com/news/home/20250804141388/en/ Niagen Bioscience Media Contact: Kendall Knysch , Senior Director of Media Relations & Partnerships 310.405.5227 [email protected] Niagen Bioscience Investor Relations Contact: ICR, LLC Reed Anderson (646) 277-1260 Stephanie Carrington (646) 277-1282 [email protected] Source: Niagen Bioscience, Inc

View stock analysis, news, and events for Niagen Bioscience, Inc.